Crucial role for interferon γ in the synergism between tumor vasculature-targeted tumor necrosis factor α (NGR-TNF) and doxorubicin

Cancer Research

Volumn 64, Issue 19, 2004, Pages 7150-7155

  Sacchi, Angelina ^a   Gasparri, Anna ^a   Curnis, Flavio ^a   Bellone, Matteo ^a   Corti, Angelo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; GENETIC TRANSFECTION; IMMUNOCOMPETENT CELL; KNOCKOUT MOUSE; MELANOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DOXORUBICIN; DRUG SYNERGISM; FEMALE; INTERFERON TYPE II; MAMMARY NEOPLASMS, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4944230230     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1445     Document Type: Article

References (55)

1. Fiers W. Biologic therapy with TNF: preclinical studies. In: De Vita V, Hellman S, Rosenberg S, editors. Biologic therapy of cancer: principles and practice. Philadelphia: J. B. Lippincott Company; 1995. p. 295-327.
2. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10: 52-60.
3. Lejeune FJ, Kroon BB, Di Filippo F, et al. Isolated limb perfusion: the European experience. Surg Oncol Clin N Am 2001;10:821-32.
4. Fraker DL, Alexander HR, Pass HI. Biologic therapy with TNF: systemic administration and isolation-perfusion. In: De Vita V, Hellman S, Rosenberg S. editors. Biologic therapy of cancer: principles and practice. Philadelphia: J. B. Lippincott Company; 1995. p. 329-45.
5. Eggermont AM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996;14:2653-65.
6. Lejeune FJ. High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. Eur J Cancer 1995;31A:1009-16.
7. Rossi CR, Foletto M, Di Filippo F, et al. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer (Phila.) 1999;86:1742-9.
8. Renard N, Lienard D, Lespagnard L, et al. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int J Cancer 1994;57:656-63.
9. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996;14:479-89.
10. Curnis F, Sacchi A, Borgna L, et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000;18:1185-90.
11. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Investig 2002;110:475-82.
12. v integrin ligands improves its antineoplastic activity. Cancer Res 2004;64:565-71.
13. Nawroth P, Handley D, Matsueda G, et al. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J Exp Med 1988;168:637-47.
14. Shimomura K, Manda T, Mukumoto S, et al. Recombinant human tumor necrosis factor-alpha: thrombus formation is a cause of anti-tumor activity. Int J Cancer 1988;41:243-7.
15. Watanabe N, Niitsu Y, Umeno H, et al. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 1988;48:2179-83.
16. Umeno H, Watanabe N, Yamauchi N, et al. Enhancement of blood stasis and vascular permeability in meth-A tumors by administration of hyperthermia in combination with tumor necrosis factor. Jpn J Cancer Res 1994;85:325-30.
17. van der Veen AH, de Wilt JH, Eggermont AM, et al. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 2000;82:973-80.
18. de Wilt JH, ten Hagen TL, de Boeck G, et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000;82:1000-3.
19. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (Wash. DC) 1998;279:377-80.
20. Pasqualini R. Vascular targeting with phage peptide libraries. Quarterly J Nucl Med 1999;43:159-62.
21. v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997;15:542-6.
22. Farrar MA, Schreiber RD, The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 1993;11:571-611.
23. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997;15:749-95.
24. Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000;1:475-82.
25. Munder M, Mallo M, Eichmann K, Modolell M. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med 1998;187:2103-8.
26. Ibe S, Qin Z, Schuler T, Preiss S, Blankenstein T. Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med 2001;194:1549-59.
27. Rottenberg ME, Gigliotti-Rothfuchs A, Wigzell H. The role of IFN-gamma in the outcome of chlamydial infection. Curr Opin Immunol 2002;14:444-51.
28. de Kossodo S, Moore R, Gschmeissner S, et al. Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis. Br J Cancer 1995;72:1165-72.
29. Brouckaert PG, Leroux-Roels GG, Guisez Y, Tavernier J, Fiers W. In vivo antitumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma. Int J Cancer 1986;38: 763-9.
30. Thom AK, Fraker DL, Taubenberger JK, Norton JA. Effective regional therapy of experimental cancer with paralesional administration of tumour necrosis factor-alpha + interferon-gamma. Surg Oncol 1992;1:291-8.
31. 3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998;4:408-14.
32. Williamson BD, Carswell EA, Rubin BY, Prendergast JS, Old LJ. Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Nad Acad Sci USA 1983;80:5397-401.
33. Fransen L, Van der Heyden J, Ruysschaert R, Fiers W. Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol 1986;22:419-26.
34. Celik C, Lewis DA, Goldrosen MH. Demonstration of immunogenicity with the poorly immunogenic B16 melanoma. Cancer Res 1983;43:3507-10.
35. Moro M, Pelagi M, Fulci G, et al. Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha. Cancer Res 1997;57:1922-8.
36. Nanni P, de Giovanni C, Lollini PL, Nicoletti G, Prodi G. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin Exp Metastasis 1983;1:373-80.
37. Gribaudo G, Cofano F, Prat M, Landolfo S. Monoclonal antibodies to murine interferon-gamma: affinity purification and molecular characterization of murine interferon-gamma. J Interferon Res 1985;5:199-208.
38. Smith RA, Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem 1987;262:6951-4.
39. Gasparri A, Moro M, Curnis F, et al. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models. Cancer Res 1999;59:2917-23.
40. Pelleitier M, Montplaisir S. The nude mouse: a model of deficient T-cell function. Methods Achiev Exp Pathol 1975;7:149-66.
41. Furrer M, Altermatt HJ, Ris HB, et al. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system. Melanoma Res 1997;7:S43-9.
42. Wong RK, Baldwin, AL Heimark RL. Cadherin-5 redistribution at sites of TNF-alpha and IFN-gamma-induced permeability in mesenteric venules. Am J Physiol 1999; 276:H736-48.
43. Shaw SK, Perkins BN, Lim YC, et al. Reduced expression of junctional adhesion molecule and platelet/endothelial cell adhesion molecule-1 (CD31) at human vascular endothelial junctions by cytokines tumor necrosis factor-alpha plus interferon-gamma does not reduce leukocyte transmigration under flow. Am J Pathol 2001;159:2281-91.
44. 3) in human endothelial cells. J Biol Chem 1991;266:7638-45.
45. Pober JS, Lapierre LA, Stolpen AH, et al. Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species. J Immunol 1987;138:3319-24.
46. Slowik MR, De Luca LG, Fiers W, Pober JS. Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration. Am J Pathol 1993;143:1724-30.
47. Jirik FR, Podor TJ, Hirano T, et al. Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol 1989;142: 144-7.
48. Nawroth PP, Bank I, Handley D, et al. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 1986;163: 1363-75.
49. Nawroth PP, Stem DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163:740-5.
50. Estrada C, Gomez C, Martin C, Moncada S, Gonzalez C. Nitric oxide mediates tumor necrosis factor-alpha cytotoxicity in endothelial cells. Biochem Biophys Res Comm 1992;186:475-82.
51. Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993;73:205-9.
52. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002;13:95-109.
53. Lienard D, Eggermont AM, Koops HS, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999;9:491-502.
54. Manusama ER, De Wilt JH, Ten Hagen TL, Marquet RL, Eggermont AM. Toxicity and antitumor activity of interferon gamma alone and in combinations with TNFalpha and melphalan in isolated limb perfusion in the BN175 sarcoma tumor model in rats. Oncol Rep 1999;6:173-7.
55. Eggermont AM, de Wilt, JH ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003;4:429-37.